Overview
- Eli Lilly’s new oral weight-loss pill, Foundayo, logged 3,707 U.S. prescriptions in its second week after launch, up from 1,390 in week one but far below Novo Nordisk’s Wegovy pill at 18,410 in its week two.
- Deutsche Bank had projected roughly 8,000 second-week scripts for Foundayo, highlighting how actual uptake missed some early Wall Street expectations.
- Investors sold Lilly stock after the weekly data were reported, and Novo Nordisk shares rose as the launch comparison favored Wegovy.
- Lilly told investors that early weekly prescription tallies may be incomplete because some pharmacy partners are not yet fully reflected, and that the figures are better judged over time.
- Lilly’s broader obesity and diabetes franchise held its ground, with combined Mounjaro, Zepbound, and Foundayo prescriptions edging down about 0.3% week over week as the company kept roughly 59% of weekly new GLP-1 prescriptions, a class used for diabetes and weight loss.